Aveo Pharms Drug Patent Portfolio
Aveo Pharms owns 1 orange book drug protected by 3 US patents Given below is the list of Aveo Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11504365 | Use of tivozanib to treat subjects with refractory cancer | 05 Nov, 2039 | Active |
| US6821987 | Quinoline derivatives and quinazoline derivatives having azolyl group | 26 Apr, 2025 | Active |
| US7166722 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | 16 Nov, 2024 | Expired |
Latest Legal Activities on Aveo Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aveo Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Interim Patent Term Extension Granted
Critical
| 18 Mar, 2024 | US6821987 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US6821987 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US7166722 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US7166722 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US6821987 |
|
Interim Patent Term Extension Granted
Critical
| 05 Oct, 2023 | US7166722 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 Aug, 2023 | US7166722 |
|
Email Notification
Critical
| 15 Aug, 2023 | US7166722 |
|
Electronic Review
Critical
| 15 Aug, 2023 | US7166722 |
|
Email Notification
Critical
| 14 Aug, 2023 | US6821987 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Aug, 2023 | US6821987 |
|
Electronic Review
Critical
| 14 Aug, 2023 | US6821987 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 25 Jan, 2023 | US11504365 |
|
Interim Patent Term Extension Granted
Critical
| 24 Jan, 2023 | US6821987 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 22 Nov, 2022 | US11504365 |
Aveo Pharms's Family Patents
Aveo Pharms Drug List
Given below is the complete list of Aveo Pharms's drugs and the patents protecting them.
1. Fotivda
Fotivda is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11504365 | Use of tivozanib to treat subjects with refractory cancer |
05 Nov, 2039
(14 years from now)
| Active |
| US6821987 | Quinoline derivatives and quinazoline derivatives having azolyl group |
26 Apr, 2025
(4 months from now)
| Active |
| US7166722 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
16 Nov, 2024
(a month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fotivda's drug page